Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces its financial reporting schedule for 2017*:
Publication | Date* | ||
2016 full-year results | Thursday, April 6th, 2017 Before the market opening | ||
Annual shareholders meeting | Wednesday, May 10th, 2017 | ||
2017 first-half results | Thursday, Septembre 28th, 2017 After the market close |
*This schedule is indicative and subject to change.
ABOUT BIOCORP
Founded in 2004 in Issoire (near
Clermont-Ferrand), France, Biocorp is a French company specializing in
the development and manufacturing of medical devices and innovative drug
delivery systems. It is listed as ‘Innovative Company’ by the French
public investment bank Bpifrance. With over twenty years of experience
and more than 30 manufactured products, Biocorp is a key player in the
industry, providing drug delivery solutions that meet the evolving needs
of patients. Today, Biocorp continues to innovate in the area of medical
plastics, its core business, and to market traditional devices
(alternative to aluminum capsules, syringe and vial administration
systems) that have been an important source of recurring income. Its
solid expertise and capacity to innovate have allowed the company to
develop new Internet-connected products, including: the DataPen, a
reusable smart injection pen that automatically transmits data to a
mobile app, helping patients to manage their treatment; and treatment
management add-ons, which adapt to existing delivery devices and are
compatible with most injection pens in the market. The company has a
team of 44 employees.
Biocorp is listed on Alternext since July
2015 (FR0012788065 – ALCOR).
For more information, please visit: www.biocorp.fr
Follow
us on Twitter @BIOCORPSystems
View source version on businesswire.com: http://www.businesswire.com/news/home/20170110005739/en/